28639-24-9

Basic information

• Product Name: dl-trans-Mesembrin
• CAS NO: 28639-24-9
• Molecular Weight: 289.375
• Mol File: 28639-24-9.mol
• Article Data: 16

Chemical Properties

• CAS DataBase Reference: dl-trans-Mesembrin(CAS DataBase Reference)
• NIST Chemistry Reference: dl-trans-Mesembrin(28639-24-9)
• EPA Substance Registry System: dl-trans-Mesembrin(28639-24-9)

Safety Data

• Hazardous Substances Data: 28639-24-9(Hazardous Substances Data)

Upstream product

• 35714-44-4 Δ7-mesembrenone 
• 70779-49-6 4,4-ethylenedioxy-1-(3',4'-dimethoxyphenyl)cyclohexene 
• 20802-16-8 1-(3,4-dimethoxyphenyl)cyclopropanecarbaldehyde 
• 78-94-4 methyl vinyl ketone 
• 74-89-5 methylamine 
• 20802-17-9 1-(3,4-Dimethoxy-phenyl)-1-methyl-iminomethyl-cyclopropan 
• 79215-01-3 {2-[9-(3,4-Dimethoxy-phenyl)-1,5-dithia-spiro[5.5]undec-7-en-9-yl]-ethyl}-methyl-amine 
• 37629-85-9 (2E)-3-(3,4-dimethoxyphenyl)prop-2-enenitrile 
• 120-14-9 3,4-dimethoxy-benzaldehyde 
• 79214-95-2 4-(cyanomethyl)-4-(3,4-dimethoxyphenyl)cyclohex-2-en-1-one 
• 79214-92-9 3-(3,4-Dimethoxy-phenyl)-4-nitro-butyronitrile 
• 189364-08-7 (S)-N-allyl-2-(3,4-dimethoxyphenyl)-2-cyclohexen-1-ylamine 
• 189364-06-5 Carbonic acid 2-(3,4-dimethoxy-phenyl)-cyclohex-2-enyl ester methyl ester 
• 122775-35-3 3,4-Dimethoxyphenylboronic acid 

Downstream Products

• 82545-07-1 4-(3,4-dimethoxyphenyl)-4-<2-(acetylmethyloamino)ethyl>cyclohexanone 
• 82545-09-3 4-(3,4-dimethoxyphenyl)-4-<2-(acetylethylamino)ethyl>cyclohexenone 

Relevant articles and documents

Palladium-catalyzed asymmetric direct intermolecular allylation of α-aryl cyclic vinylogous esters: Divergent synthesis of (+)-oxomaritidine and (?)-mesembrine

We demonstrate that α-aryl cyclic vinylogous esters are competent substrates in the direct intermolecular Pd-catalyzed asymmetric allylic alkylation, enabling a straightforward enantioselective synthesis of 6-allyl-6-aryl-3-ethoxycyclohex-2-en-1-ones, common motifs embedded in numerous structurally diverse natural products. As an initial demonstration of the utility of this protocol, the first catalytic enantioselective total synthesis of (+)-oxomaritidine and an improved five-step catalytic enantioselective synthesis of (?)-mesembrine have been completed divergently.

Highly chemoselective aerobic oxidation of amino alcohols into amino carbonyl compounds

The direct oxidation of unprotected amino alcohols to their corresponding amino carbonyl compounds has often posed serious challenges in organic synthesis and has constrained chemists to adopting an indirect route, such as a protection/deprotection strategy, to attain their goal. Described herein is a highly chemoselective aerobic oxidation of unprotected amino alcohols to their amino carbonyl compounds in which 2-azaadamantane N-oxyl (AZADO)/copper catalysis is used. The catalytic system developed leads to the alcohol-selective oxidation of various unprotected amino alcohols, carrying a primary, secondary, or tertiary amino group, in good to high yield at ambient temperature with exposure to air, thus offering flexibility in the synthesis of nitrogen-containing compounds. Strong as an ox: The highly chemoselective aerobic oxidation of unprotected amino alcohols to their corresponding amino carbonyl compounds has been achieved by using 2-azaadamantane N-oxyl (AZADO)/copper catalysis. This catalytic system oxidizes not only alcohols with tertiary amino groups but also those with secondary and primary amines in good to high yield at ambient temperature in air. bpy=2,2-bipyridyl, DMAP=4-(N,N-dimethylamino)pyridine.

Substituted urea-octatydroindols as antagonists of melanin concentrating hormone receptor 1 (MCH1R)

The invention relates to compounds of the general formula (I) wherein R0, R1, R2, R3, R4, R5, R6, R7, R8, R9, Ar, and X are as defined in the description, or a pharmaceutically acceptable salt, hydrates, geometrical isomers, racemates, tautomers, optical isomers, N-oxides and prodrug forms thereof. The compounds may be used for the treatment or prophylaxis of disorders related to the MCH1R receptor and for modulation of appetite. The invention also relates to such use as well as to pharmaceutical formulations comprising a compound of formula (I).